Media Thread, page-15270

for layman like me just a translation

The Phase II HERIZON trial evaluated HER-Vaxx, a B-cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients. The study showed a 40% overall survival (OS) benefit for patients receiving HER-Vaxx plus chemotherapy compared to chemotherapy alone. No additional toxicity from HER-Vaxx was observed. The vaccine induced strong HER2-specific antibody responses, which correlated with tumor reduction and improved OS. The results suggest HER-Vaxx could be a potential alternative to trastuzumab, especially when the latter is unavailable or not tolerated

Comparison of HER-Vaxx with Standard Care and Competing Products

Standard Care (Chemotherapy + Trastuzumab):

• Trastuzumab is the current standard for HER2-overexpressing advanced gastric cancer, combined with chemotherapy.
• Effectiveness: It has shown improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone.
• Limitations: Possible toxicity and availability issues.

HER-Vaxx (HERIZON Trial):

• Combination: HER-Vaxx + chemotherapy.
• Results: 40% OS benefit, 20% PFS benefit, no additional toxicity. High HER2-specific antibody response, leading to tumor reduction.
• Potential: May substitute trastuzumab in cases of unavailability or toxicity.

Competing Products in Clinical Trials:

• Other HER2-targeted Therapies:
  • Zanidatamab (ZW25): Dual HER2-targeted bispecific antibody; in clinical trials showing promising efficacy in HER2-positive cancers.
  • Margetuximab: HER2-targeted monoclonal antibody; enhances antibody-dependent cellular cytotoxicity (ADCC) more effectively than trastuzumab.
  • DS-8201 (Trastuzumab Deruxtecan): Antibody-drug conjugate showing significant efficacy in HER2-positive tumors.